RT Journal Article
SR Electronic
T1 Bovine Colostrum Derived Antibodies Against SARS-CoV-2 Show Great Potential to Serve as a Prophylactic Agent
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.08.21258069
DO 10.1101/2021.06.08.21258069
A1 Kadri Kangro
A1 Mihhail Kurašin
A1 Kiira Gildemann
A1 Eve Sankovski
A1 Eva Žusinaite
A1 Laura Sandra Lello
A1 Raini Pert
A1 Ants Kavak
A1 Väino Poikalainen
A1 Lembit Lepasalu
A1 Marilin Kuusk
A1 Robin Pau
A1 Sander Piiskop
A1 Siimu Rom
A1 Ruth Oltjer
A1 Kairi Tiirik
A1 Karin Kogermann
A1 Mario Plaas
A1 Toomas Tiirats
A1 Birgit Aasmäe
A1 Mihkel Plaas
A1 Dagni Krinka
A1 Ene Talpsep
A1 Meelis Kadaja
A1 Joachim M. Gerhold
A1 Anu Planken
A1 Andres Tover
A1 Andres Merits
A1 Andres Männik
A1 Mart Ustav, Jr
A1 Mart Ustav
YR 2021
UL http://medrxiv.org/content/early/2021/07/27/2021.06.08.21258069.abstract
AB Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) until now imposes a serious burden to health systems globally. Despite worldwide vaccination, social distancing and wearing masks, the spread of the virus is still ongoing. One of the mechanisms how neutralizing antibodies (NAbs) block virus entry into cells encompasses interaction inhibition between the cell surface receptor angiotensin-converting enzyme 2 (ACE2) and the spike (S) protein of SARS-CoV-2. SARS-CoV-2 specific NAb development can be induced in the blood of cattle. Pregnant cows produce NAbs upon immunization, and antibodies move into the colostrum just before calving. Here we immunized cows with SARS-CoV-2 S1 receptor binding domain (RBD) protein in proper adjuvant solutions, followed by one boost with SARS-CoV-2 trimeric S protein, and purified immunoglobulins from colostrum. We demonstrate that this preparation indeed blocks interaction between the trimeric S protein and ACE2 in different in vitro assays. Moreover, we describe the formulation of purified immunoglobulin preparation into a nasal spray. When administered to human subjects, the formulation persists on the nasal mucosa for at least 4 hours as determined by a clinical study. Therefore, we are presenting a solution that shows great potential to serve as a prophylactic agent against SARS-CoV-2 infection as an additional measure to vaccination and wearing masks. Moreover, our technology allows for a rapid and versatile adaption for preparing prophylactic treatments against other diseases by using the defined characteristics of antibody movement into the colostrum.Significance SARS-CoV-2 infections continue to be a high-risk factor for mankind. Antibodies with the potential to neutralize the virus and thus its entry into the host cell have been shown to impose a potent measure against the infection. Human derived neutralizing antibodies are therapeutics and thus fall under the legislation of drugs. However, an alternative could be the purification of efficient neutralizing antibodies from other species. Here, we present immunization of pregnant cows with spike protein of SARS-CoV-2 which results in high quantities of colostrum immunoglobulins that can be easily harvested and safely purified within a remarkably short time. The colostrum immunoglobulin preparation has a great potential to serve in formulations that can be used as prophylactic agent against SARS-CoV-2 infection.Competing Interest StatementThe use of bovine colostrum as a prophylactic agent against SARS-CoV-2 has been patented (US patent application no 63/160,833) by Mario Plaas, K. Kogermann, E. Zusinaite, T. Tiirats, B. Aasmae, A. Kavak, V. Poikalainen, L. Lepasalu, S. Piiskop, S. Rom, R. Oltjer, K. Kangro, E. Sankovski, J. M. Gerhold, R. Pert, A. Mannik, A. Planken, A. Tover, M. Kurasin, M. Ustav and M. Ustav Jr.Clinical TrialTo test the nasal biological availability of the bovine colostrum immunoglobulin preparation a clinical study on 16 healthy volunteers was conducted in accordance with the Declaration of Helsinki and approval was granted by the Tartu University Ethics Committee on March 17th 2021 (approval number 336/T-1). The trial was registered at ClinicalTrials.gov; ClinicalTrials.gov Identifier: NCT04916574Funding StatementThis study was supported by the funding from Enterprise Estonia grant number 2014-2020.4.02.21-0317.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:To test the nasal biological availability of the bovine colostrum immunoglobulin preparation a clinical study on 16 healthy volunteers was conducted in accordance with the Declaration of Helsinki and approval was granted by the Tartu University Ethics Committee on March 17th 2021 (approval number 336/T-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData presented in the manuscript will be made available upon contacting the corresponding author. The use of bovine colostrum as a prophylactic agent against SARS-CoV-2 has been patented (US patent application no 63/160,833) by Mario Plaas, K. Kogermann, E. Zusinaite, T. Tiirats, B. Aasmae, A. Kavak, V. Poikalainen, L. Lepasalu, S. Piiskop, S. Rom, R. Oltjer, K. Kangro, E. Sankovski, J. M. Gerhold, R. Pert, A. Mannik, A. Planken, A. Tover, M. Kurashin, M. Ustav and M. Ustav Jr.